CTLA4 and melanoma: As a representative sample of the anti-CTLA4 antibody, ipilimumab has been approved for melanoma therapy by the FDA in 2010, which is an immunomodulatory monoclonal IgG1 antibody directed against the cell surface antigen CTLA4 (25).